We read with interest the paper by Burkoff et al. (1) proposing mechanical assist solution for heart failure with preserved ejection fraction (HFpEF) We believe addition of left atrial parameters will aid in better selection of patients for such a pump as they act as valuable surrogates of the primary driver of hemodynamic abnormality and morbidity in HFpEF (4).
Is Pump the Answer to Heart Failure With Preserved Ejection Fraction?
We read with interest the paper by Burkoff et al. (1) proposing mechanical assist solution for heart failure with preserved ejection fraction (HFpEF). Treatment of HFpEF is particularly difficult due to multiple cardiac and extra cardiac influences on symptomatology and disease process (2) We believe addition of left atrial parameters will aid in better selection of patients for such a pump as they act as valuable surrogates of the primary driver of hemodynamic abnormality and morbidity in HFpEF (4).
Secondly the presence of pulmonary hypertension has been shown to be consistently associated with worse prognosis in patients with HFpEF. Including pulmonary hypertension would help further risk stratify these patients and provide an objective measure which is not included in traditional risk stratification models of heart failure (5). Finally, we would like to congratulate the authors in providing this conceptual frame work and we hope application of these concepts translates into a clinical trial to address this vexing problem. Please note: Dr. Estep is a consultant to Thoratec Corporation, and Maquet. Dr. Guha has reported that he has no relationships relevant to the contents of this paper to disclose.
as employed by the CircuLite system (HeartWare, Framingham, Massachusetts) a seemingly ideal approach. As they appropriately noted, it is possible that chronic unloading of the LA may result in reverse LA remodeling with reduction of LA size, leading to conditions vulnerable to suction events and thrombus formation. However, LA size reduction was not noted as a significant problem in our experience of using the CircuLite system with properly placed inflow cannula tip for MCS in patients with reduced ejection fraction heart failure (HFrEF) (2) . Nevertheless, our ongoing bench and animal studies to improve the system include efforts to further optimize inflow cannula tip design and position to minimize occurrences of LA suction. Incorporation of a suction algorithm will further help mitigate such issues.
As more is known about mechanisms underlying HFpEF in specific subgroups the more likely it will be that efforts to develop medical therapies for HFpEF will be successful. However, as for HFrEF, it is also likely that medical therapies will delay, not prevent disease progression or cure the disease. For those patients, we believe the development of an MCS option may prove beneficial. We hope that in addition to Drs. Guha and Estep, others will join the discussion early and help in this effort so that we can arrive at a solution in a timely manner.
